Kezar Life Sciences (KZR) Q3 2025 earnings summary

Executive summary

• Focused on developing small molecule therapeutics for immune-mediated diseases, with zetomipzomib as the lead candidate targeting autoimmune hepatitis (AIH) and other indications.

• Initiated a strategic review process after failing to align with the FDA on a registrational trial for zetomipzomib in AIH, including cost containment and a 70% workforce reduction.

• Retained TD Cowen to support the strategic review and implemented a restructuring plan reducing headcount by 70%.

• No products approved for sale; operations funded primarily through equity, debt, and a collaboration agreement with Everest Medicines.

Financial highlights

• Net loss of $11.2 million for Q3 2025, improved from $20.3 million in Q3 2024; net loss of $41.5 million for the nine months ended September 30, 2025, compared to $63.5 million in the prior year period.

• Research and development expenses for Q3 2025 decreased to $6.9 million from $16.2 million in Q3 2024, mainly due to program terminations and lower personnel costs.

• General and administrative expenses for Q3 2025 were $4.8 million, down from $5.7 million in Q3 2024, primarily due to lower stock-based compensation and personnel costs.

• Cash, cash equivalents, and marketable securities totaled $90.2 million as of September 30, 2025, down from $132.2 million at year-end 2024.

• Restructuring and impairment charges of $1.5 million recognized in Q3 2025.

Outlook and guidance

• Cash resources are expected to fund operations for at least the next 12 months.

• Exploring a full range of strategic alternatives to maximize shareholder value, with cost containment and cash conservation measures in place.

• Research and development and general and administrative expenses are expected to remain flat or decrease due to program suspensions and workforce reductions.

• If no strategic transaction is completed, dissolution and liquidation may be considered.

• Majority of restructuring costs expected to be recognized in Q4 2025.